It estimates the 2014 sales for growth hormone deficiency (GHD) at approximately $1.26 billion across the 7MM covered in this report. The market will grow moderately at a CAGR of 4.08% during the 10-year forecast period, generating sales of approximately $1.88 billion at the end of 2024. The US market is expected to grow the fastest of the three regions, recording a CAGR of 4.88% and generating around 59% of global sales in 2024. The major driver for this growth across the 7MM will be the launch of long-acting biobetter growth hormones (GH), which will rapidly take away shares from the currently marketed daily injectable growth hormones.
– The major driver for growth in the GHD market during the forecast period will be the launch of six long-acting GH biobetters with less frequent dosing regimens. These will not only boost the use of GH, but will in addition increase adherence and compliance in patients.
– KOLs interviewed by GlobalData opined that these long-acting biobetters will eventually replace most of the patient shares of currently marketed GH drugs during the forecast period.
– In other interviews, US payers revealed to GlobalData the current trend of GH manufacturers negotiating with insurance companies as a means of gaining market access for their particular brand.
– Low disease awareness and stringent regulatory policies lead to sub-optimal dosing and treatment outcomes in the Japanese market.
– Companies in the early-stage GHD space demonstrate two major trends – development of long-acting GH formulations and innovation in GH delivery strategies.
